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Introduction
Cocaine is the second most commonly used illicit drug in
the United States, 1 and is the most frequent illicit substance
to precipitate an emergency room visit, responsible for over
550,000 visits in 2007 alone. 2 The majority of patients present
with a chief complaint of chest pain3, and approximately 6%
are diagnosed with cocaine associated myocardial infarction.4
For decades it has been thought that beta-blockade in the
setting of cocaine use would precipitate coronary vasospasm
and worsen cardiovascular outcomes due to unopposed alpha
receptor stimulation. In 1999 this thinking was incorporated
into the ACC/AHA guidelines, which currently recommend
beta-blockers in all patients with an acute coronary syndrome
except in the setting of prior cocaine use.4 Recently there have
been several studies suggesting benefit from beta-blocker
administration in patients with cocaine associated chest pain
and myocardial ischemia.
Given the recent data that call into question the validity of
avoiding beta-blockers in patients with recent cocaine use, the
goal of this article is to critically review the body of evidence that
exists on beta-blocker usage in the setting of cocaine induced
chest pain and myocardial ischemia.
Based on our findings it is clear that the current recommendations and theories need to be scrutinized and that additional
outcomes based, randomized prospective human trials be
conducted to effectively examine the possible benefits of
beta-blocker usage in these patients.

Methods
We performed a comprehensive search of the medical literature
concerning beta-blocker usage in the setting of cocaine
intoxication, and cocaine associated chest pain and myocardial
ischemia. The literature search was conducted using PUB Med
and included English language publications from 1960-2010.
Keywords: Cocaine, beta-blockers, cocaine chest pain, MI,
emergency department.

Current ACC/AHA Guidelines For Beta-blockers in Acute
Coronary Syndrome
Beta-blockers have been shown by multiple large randomized
trials to decrease mortality in patients presenting with cardiac
ischemia and ST-elevation myocardial infarction (STEMI).
In the ISIS-1 trial, more than 16,000 patients with suspected
acute MI were enrolled within 12 hours of onset of symptoms.
Subjects receiving atenolol therapy showed a reduction in 7-day
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mortality from 4.3% to 3.7% (p <0.02).7 In the Metoprolol In
Acute Myocardial Infarction (MIAMI) trial, more than 5700
subjects with evolving MI were randomly assigned to receive
placebo or metoprolol. Fifteen-day mortality was reduced with
metoprolol from 4.9% to 4.3%.9 These trials form the basis of the
ACC/AHA guidelines, which recommend beta-blocker therapy
in all patients with STEMI5, as well as NSTEMI/Unstable
angina6, as long as there are no contraindications.

Beta-blocker Usage in the Setting of Cocaine
Associated Chest Pain/ACS
The guidelines go on to state that “Beta-blockers should not be
administered to patients with STEMI precipitated by cocaine
use because of the risk of exacerbating coronary spasm,”5 citing
a review article by Kloner et al.8 published in Circulation in
1993. This article discusses the possibility of coronary vasoconstriction following beta-blocker administration in the setting of
recent cocaine use, citing studies by Shannon et al.10 and Lange
et al.11
Shannon et al., 10 administered cocaine followed by a beta-blocker
to ten canine subjects while continually monitoring systemic and
coronary hemodynamics. This study found that beta blockade in
the setting of cocaine intoxication worsened coronary vasoconstriction, and decreased coronary blood flow.10
Lange et al.11 conducted the only prospective human trial to
examine the effect of beta-selective blockade on coronary
artery hemodynamics in the setting of cocaine. This article is
the primary source cited throughout the medical literature
when discussing beta-blocker usage in the setting of cocaine
chest pain and ACS. In this study, ten human subjects received
intracoronary propranolol following intranasal cocaine
administration. Similar to the canine study, Lange et al., found
a significant increase in coronary vascular resistance, and a
decrease in coronary sinus blood flow.11
The only other human study that has looked at coronary blood
flow following beta blockade in the setting of cocaine intoxication
was published by Boehrer et al.,12 three years after Lange’s article.
This study looked at coronary artery area following intranasal
cocaine and then administration of labetalol, a combination
alpha and beta-blocker. Contrary to Lange’s findings, the nine
patients that received cocaine followed by labetalol did not show
a decrease in coronary artery area.12
Thus, these three studies comprise the entirety of the literature
evaluating this topic, and form the basis for the current national
guidelines. With only two prospective human studies involving
a total of 19 patients and contradictory results, it is not possible
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to draw a valid evidence-based conclusion on the cardiovascular
effects of beta blockade in the setting of cocaine intoxication.
More data regarding coronary perfusion as well as actual patient
outcomes are needed before firm recommendations can be
drawn regarding beta-blocker usage in this setting.

Beta-blockers Effect on Systemic Hemodynamic Parameters and Outcome
Though not specifically mentioned as a reason for beta-blocker
avoidance in the ACC/AHA guidelines, beta-blockers in the
setting of recent cocaine use have long been hypothesized to
worsen systemic hypertension and tachycardia, and possibly
precipitate myocardial ischemia due to increased cardiac oxygen
demand. The mechanism is attributed to unopposed alphareceptor stimulation leading to worsening systemic vasoconstriction.13 In this area, the evidence is equally inconsistent, with
newer research concluding that beta-blockers may actually be
beneficial in patients with cocaine associated chest pain and
myocardial ischemia.

fact most cases have shown improved hemodynamics and more
favorable cardiovascular outcomes.

Conclusion
Given the strong evidence supporting the morbidity and
mortality benefits of beta-blockers in patients undergoing ACS,
and the weak and contradictory evidence opposing them in the
setting of cocaine use it is necessary that steps are taken to better
understand the issue. The majority of the recent data does not
show any adverse cardiovascular outcomes, and the older data
are equivocal at best.
We are possibly withholding beneficial treatment to patients
based on unclear and outdated evidence. It is necessary to further
examine the current treatment of cocaine related chest pain with
prospective, randomized human trials to best determine what is
optimal for patient outcomes.
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